Journal article

To the Editor

Dan Siskind, Michael Berk, David Castle, Anthony Harris

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY | SAGE PUBLICATIONS LTD | Published : 2020

Grants

Funding Acknowledgements

D.S. and K.N. have no conflicts of interest to declare. M.B. has had interactions in the last 5 years with Janssen-Cilag, Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Grunbiotics, LivaNova, Lundbeck, Merck, Mylan, Otsuka and Servier. D.C. has received grant monies for research from Eli Lilly, Janssen-Cilag, Roche, Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, Astra Zeneca and Hospira; travel support and honoraria for talks and consultancy from Eli Lilly, Bristol-Myers Squibb, Astra Zeneca, Lundbeck, Janssen-Cilag, Pfizer, Organon, Sanofi-Aventis, Wyeth, Hospira and Servier; and is a current Advisory Board Member for Lu AA21004: Lundbeck; Varenicline: Pfizer; Asenapine: Lundbeck; Aripiprazole LAI: Lundbeck; Lisdexamfetamine: Shire; and Lurasidone: Servier. He has no stocks or shares in any pharmaceutical company. C.G. had had clinical trials funded by Bristol-Myers Squibb Research & Development, Janssen Research & Development, ICON Clinical Research P/L, Envivo Pharmaceuticals/INC Research, and has received professional fees from Lundbeck and JanssenCilag. A.H. has received consultancy fees from Janssen Australia and Lundbeck Australia. He has been on an advisory board for Sumitomo Dainippon Pharma. He has received payments for educational sessions run for Janssen Australia and Lundbeck Australia. He has developed educational material for Servier. He is also the recipient of an investigator-initiated grant from Takeda Pharmaceutical Company.